Back

Association of lipid-lowering drug treatment with all-cause and cardiovascular mortality among people aged 75 years and above without cardiovascular disease: evidence from a cohort study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Drug therapy (2) Drug therapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Assistant Professor Zuyao Yang

The Chinese University of Hong Kong, Shatin (Hong Kong)

6 More presentations in this session

Presentation thumbnail
Bempedoic acid in clinical practice.
Doctor J. Vazquez Reguera (Las Palmas de Gran Canaria, ES)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of Alirocumab once-monthly dosing in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke; an ODYSSEY CHOICE I analysis
Doctor C. Bonanad Lozano (Valencia, ES)
Abstract Slides Video
Presentation thumbnail
LDL on target - strike early and strike strong... just strike...
Doctor L. Hamann (Faro, PT)
Abstract Slides Video
Presentation thumbnail
VICTORION IMPLEMENT: an observational study of the lipid management landscape in Germany
Professor O. Weingaertner (Jena, DE)
Abstract Slides Video
Presentation thumbnail
Analytical approaches to open label extension (OLE) after cardiovascular outocmes trials: Observations from the FOURIER and FOURIER-OLE trials
Doctor H. Wang (Newbury Park, US)
Abstract Slides Video

Access the full session

Session thumbnail
Drug therapy (2)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Lipid lowering therapy in patients aged 90 years or older with acute myocardial infarction:a multicenter cohort study
thumbnail
Congress Presentation
Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events
thumbnail
Congress Presentation
The association between remnant cholesterol and all-cause mortality and cardiovascular mortality was modified by aged in American adults: a retrospective cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources